Last €41.66 EUR
Change Today +0.277 / 0.67%
Volume 0.0
EC8 On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 2:20 AM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

conmed corp (EC8) Snapshot

Open
€41.69
Previous Close
€41.39
Day High
€41.69
Day Low
€41.66
52 Week High
01/27/15 - €42.07
52 Week Low
08/13/14 - €27.12
Market Cap
1.1B
Average Volume 10 Days
3.0
EPS TTM
--
Shares Outstanding
27.5M
EX-Date
12/11/14
P/E TM
--
Dividend
€0.73
Dividend Yield
1.45%
Current Stock Chart for CONMED CORP (EC8)

conmed corp (EC8) Related Bloomberg News

View More Bloomberg News

conmed corp (EC8) Related Businessweek News

No Related Businessweek News Found

conmed corp (EC8) Details

CONMED Corporation provides surgical devices and equipment for minimally invasive procedures and monitoring. It offers sports medicine products, including powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, metal and bioabsorbable implants, and related disposable products and fluid management systems; powered surgical instruments for use in large and small bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, plastic, ENT, neurological, spinal, and cardiothoracic surgeries; electrosurgical generators and related instruments; and 2D and 3D video systems for use in minimally invasive orthopedic and general surgeries. The company also provides patient monitoring products comprising vital signs and cardiac monitoring products, including pulse oximetry equipment and sensors, ECG electrodes and cables, cardiac defibrillation and pacing pads, and blood pressure cuffs; surgical suction instruments and tubing products; and IV products used in critical care areas. In addition, it offers endomechanical instrumentation products, such as trocars, clip appliers, scissors, and surgical staplers used in the minimally invasive laparoscopic and gynecological surgery. Further, the company provides gastrointestinal and pulmonary products consisting of minimally invasive diagnostic and therapeutic products, including mucosal management devices, forceps, scope management accessories, bronchoscopy devices, dilatation, stricture management devices, hemostasis, biliary devices, and polypectomy. Its products are used by surgeons and physicians in orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology. The company operates in the United States, Canada, the United Kingdom, Japan, Australia, and internationally. CONMED Corporation was founded in 1970 and is headquartered in Utica, New York.

3,500 Employees
Last Reported Date: 01/27/15
Founded in 1970

conmed corp (EC8) Top Compensated Officers

Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $320.8K
Principal accounting Officer, Executive Vice ...
Total Annual Compensation: $316.9K
General Counsel and Executive Vice President ...
Total Annual Compensation: $290.6K
Compensation as of Fiscal Year 2013.

conmed corp (EC8) Key Developments

CONMED Corporation Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Updates Earnings Guidance for the Full Year 2015

CONMED Corporation reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, net sales were $195,003,000 against $203,442,000 a year ago. Income from operations was $17,089,000 against $16,181,000 a year ago. Income before income taxes was $15,550,000 against $14,699,000 a year ago. Net income was $11,339,000 or $0.41 per basic and diluted share against $10,227,000 or $0.36 per diluted share a year ago. Adjusted income from operations was $22,389,000 against $23,203,000 a year ago. EBITDA was $28,657,000 against $28,361,000 a year ago. Adjusted EBITDA was $35,213,000 against $36,874,000 a year ago. Cash provided by operations was very strong at $27.3 million in the fourth quarter. Adjusted net income was $14,731,000 or $0.53 per diluted share against $14,898,000 or $0.53 per diluted share a year ago. Diluted earnings per share on a GAAP basis for the December 2014 quarter improved over the fourth quarter of 2013 due to lower operating expenses, including lower special items. Diluted earnings per share on a GAAP basis for the December 2014 quarter improved over the fourth quarter of 2013 due to lower operating expenses, including lower special items. Adjusting for the special items in both quarterly periods, adjusted diluted EPS was the same in both periods, as lower sales and gross margin in the fourth quarter of 2014 were offset by lower operating costs, a lower tax rate and reduced shares outstanding as compared to the fourth quarter of 2013. For the full year, net sales were $740,055,000 against $762,704,000 a year ago. Income from operations was $52,786,000 against $56,508,000 a year ago. Income before income taxes was $46,675,000 against $50,632,000 a year ago. Net income was $32,192,000 or $1.16 per diluted share against $35,939,000 or $1.28 per diluted share a year ago. Net cash provided by operating activities was $65,176,000 against $80,949,000 a year ago. Purchases of property, plant, and equipment were $15,411,000 against $18,445,000 a year ago. Adjusted income from operations was $82,360,000 against $78,533,000 a year ago. EBITDA was $97,936,000 against $103,816,000 a year ago. Adjusted EBITDA was $132,929,000 against $131,434,000 a year ago. Adjusted net income was $53,378,000 or $1.16 per diluted share against $50,754,000 or $1.28 per diluted share a year ago. GAAP diluted earnings per share declined 9.4% caused by lower sales and higher costs for special items, particularly for those associated with management restructuring, Denver plant consolidation, and shareholder activism. Adjusting for the special items in both years as indicated on the following reconciliation, adjusted earnings per share grew 6.1% due to lower operating costs. The company updated earnings guidance for the year 2015. The company has outlined certain changes in the structure of its commercial organization that management believes will return the company to sales growth in 2015. The company anticipates constant currency sales growth of 1% to 3% for the full year, which will be driven by new product launches and a reorganization of certain aspects of the commercial sales organization in early 2015. As a result, the company expected revenue growth to accelerate in the second half of 2015 compared to the first half of 2015. Company’s prior 2015 guidance contemplated foreign exchange rates as of December 2014. The January 2015 volatility in the currency markets has been significant, and the company has chosen to update 2015 guidance based on currency spot rates as of the close on January 23, 2015. Based on these rates, the updated negative impact of foreign exchange rates versus 2014 is $19 million to revenues and $0.14 to EPS, versus the prior estimates of $6 million and $0.04, respectively. The company anticipated to report sales for 2015 will be in the range of $727 million to $742 million, representing a range of (2%) to 0% versus the prior year. The company continues to expect 2015 constant currency revenue growth of 1% to 3%. In addition, adjusted diluted earnings per share will be in the range of $1.82 to $1.92. The adjusted estimates for the full year 2015 exclude the cost of special items, including the manufacturing consolidation, commercial restructuring and senior management changes which are estimated to be $9.0 million to $11.0 million, net of tax, for 2015.

CONMED Corporation Announces Preliminary 2014 Results and Provides Earnings Guidance for the Year 2015

CONMED Corporation announced preliminary 2014 results. For the 2014 calendar year, the Company expects that sales will be approximately $739 - $741 million with adjusted earnings per share expected to be approximately $1.90 - $1.94. For 2015, the company expects to achieve full year sales of $740 - $755 million and adjusted earnings per share of $1.92 - $2.02.

CONMED Corporation to Report Q4, 2014 Results on Jan 27, 2015

CONMED Corporation announced that they will report Q4, 2014 results at 4:00 PM, US Eastern Standard Time on Jan 27, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EC8:GR €41.66 EUR +0.277

EC8 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Integra LifeSciences Holdings Corp $55.72 USD -1.90
Masimo Corp $25.52 USD -0.80
NuVasive Inc $46.32 USD -0.98
Paramount Bed Holdings Co Ltd ¥3,270 JPY 0.00
Wright Medical Group Inc $24.41 USD -0.75
View Industry Companies
 

Industry Analysis

EC8

Industry Average

Valuation EC8 Industry Range
Price/Earnings 41.1x
Price/Sales 1.8x
Price/Book 2.3x
Price/Cash Flow 40.7x
TEV/Sales 1.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CONMED CORP, please visit www.conmed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.